You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Attention Score in Context
| Title |
Vedolizumab (Anti-alpha4beta7) in Subjects With HIV Infection Undergoing Analytical Treatment Interruption
|
|---|---|
| Registered in |
ClinicalTrials.gov, May 2016
|
| Information provided by |
National Institutes of Health Clinical Center (CC) ( National Institute of Allergy and Infectious Diseases (NIAID) ), Sneller, Michael C |
| ClinicalTrials.gov ID |
X Demographics
The data shown below were collected from the profiles of 8 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 38% |
| Ecuador | 1 | 13% |
| Unknown | 4 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 5 | 63% |
| Practitioners (doctors, other healthcare professionals) | 3 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1060. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 August 2019.
All research outputs
#12,684
of 23,613,071 outputs
Outputs from ClinicalTrials.gov
#3
of 23,995 outputs
Outputs of similar age
#202
of 340,146 outputs
Outputs of similar age from ClinicalTrials.gov
#3
of 1,005 outputs
Altmetric has tracked 23,613,071 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 23,995 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 17.7. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 340,146 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 1,005 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.